{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:22:43Z","timestamp":1790702563218,"version":"4.1.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,20]],"date-time":"2021-01-20T00:00:00Z","timestamp":1611100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014394","name":"Baylor University Medical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014394","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jgar.2021.01.005","type":"journal-article","created":{"date-parts":[[2021,1,25]],"date-time":"2021-01-25T21:54:08Z","timestamp":1611611648000},"page":"403-410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model"],"prefix":"10.1016","volume":"24","author":[{"given":"Shashikant","family":"Srivastava","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0879-4381","authenticated-orcid":false,"given":"Moti","family":"Chapagain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"van Zyl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devyani","family":"Deshpande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2021.01.005_bib0005","series-title":"Global Tuberculosis Report 2020. Executive Summary","author":"World Health Organization (WHO)","year":"2020"},{"key":"10.1016\/j.jgar.2021.01.005_bib0010","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S2213-2600(17)30079-6","article-title":"The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis","volume":"5","author":"Dheda","year":"2017","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.jgar.2021.01.005_bib0015","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/nrmicro3299","article-title":"How sisters grow apart: mycobacterial growth and division","volume":"12","author":"Kieser","year":"2014","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2021.01.005_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/nrmicro2677","article-title":"From the regulation of peptidoglycan synthesis to bacterial growth and morphology","volume":"10","author":"Typas","year":"2011","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jgar.2021.01.005_bib0025","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/BF01967563","article-title":"Structure, biochemistry and mechanism of action of glycopeptide antibiotics","volume":"8","author":"Reynolds","year":"1989","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2021.01.005_bib0030","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/jac\/dkz061","article-title":"Once-a-week tigecycline for the treatment of drug-resistant TB","volume":"74","author":"Deshpande","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.jgar.2021.01.005_bib0035","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/infdis\/jiy587","article-title":"Minocycline immunomodulates via sonic hedgehog signaling and apoptosis and has direct potency against drug-resistant tuberculosis","volume":"219","author":"Deshpande","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2021.01.005_bib0040","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02232-17","article-title":"Antibacterial and sterilizing effect of benzylpenicillin in tuberculosis","volume":"62","author":"Deshpande","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.005_bib0045","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.1701102","article-title":"Ceftazidime\u2013avibactam has potent sterilizing activity against highly drug-resistant tuberculosis","volume":"3","author":"Deshpande","year":"2017","journal-title":"Sci Adv"},{"key":"10.1016\/j.jgar.2021.01.005_bib0050","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/febs.13738","article-title":"Crystal structures of the transpeptidase domain of the Mycobacterium tuberculosis penicillin-binding protein PonA1 reveal potential mechanisms of antibiotic resistance","volume":"283","author":"Filippova","year":"2016","journal-title":"FEBS J"},{"key":"10.1016\/j.jgar.2021.01.005_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1001020","article-title":"Interaction and modulation of two antagonistic cell wall enzymes of mycobacteria","volume":"6","author":"Hett","year":"2010","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.jgar.2021.01.005_bib0060","doi-asserted-by":"crossref","first-page":"13087","DOI":"10.1073\/pnas.1514135112","article-title":"Peptidoglycan synthesis in Mycobacterium tuberculosis is organized into networks with varying drug susceptibility","volume":"112","author":"Kieser","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jgar.2021.01.005_bib0065","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1128\/AAC.00665-12","article-title":"Inactivation of Mycobacterium tuberculosis l,d-transpeptidase LdtMt1 by carbapenems and cephalosporins","volume":"56","author":"Dubee","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.005_bib0070","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1038\/nm.2120","article-title":"The Mycobacterium tuberculosis protein LdtMt2 is a nonclassical transpeptidase required for virulence and resistance to amoxicillin","volume":"16","author":"Gupta","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.jgar.2021.01.005_bib0075","series-title":"Goodman and Gilman\u2019s: The pharmacological Basis of Therapeutics","first-page":"1049","article-title":"Protein synthesis inhibitors and miscellaneous antibacterial agents","author":"MacDougall","year":"2018"},{"key":"10.1016\/j.jgar.2021.01.005_bib0080","doi-asserted-by":"crossref","first-page":"28002","DOI":"10.1038\/srep28002","article-title":"Mycobacterium tuberculosis Rv1152 is a novel GntR family transcriptional regulator involved in intrinsic vancomycin resistance and is a potential vancomycin adjuvant target","volume":"28","author":"Zeng","year":"2016","journal-title":"Sci Rep"},{"key":"10.1016\/j.jgar.2021.01.005_bib0085","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1128\/AAC.04856-14","article-title":"Increased vancomycin susceptibility in mycobacteria: a new approach to identify synergistic activity against multidrug-resistant mycobacteria","volume":"59","author":"Soetaert","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.005_bib0090","first-page":"S194","article-title":"Pharmacokinetics of vancomycin in plasma and sputum following pulmonary administration in cystic fibrosis patients with persistent methicillin-resistant Staphylococcus aureus infection","volume":"51","author":"Marich","year":"2016","journal-title":"Pediatr Pulmonol"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2021.01.005_bib0095","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1093\/cid\/civ426","article-title":"Correlations between the hollow fiber model of tuberculosis and therapeutic events in tuberculosis patients: learn and confirm","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.01.005_bib0100","doi-asserted-by":"crossref","first-page":"2881","DOI":"10.2174\/138161211797470192","article-title":"In vitro and in vivo modeling of tuberculosis drugs and its impact on optimization of doses and regimens","volume":"17","author":"Srivastava","year":"2011","journal-title":"Curr Pharm Des"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2021.01.005_bib0105","doi-asserted-by":"crossref","first-page":"S308","DOI":"10.1093\/cid\/ciy624","article-title":"d-cycloserine pharmacokinetics\/pharmacodynamics, susceptibility, and dosing implications in multidrug-resistant tuberculosis: a Faustian deal","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.01.005_bib0110","series-title":"Mycobacteriology Laboratory Manual. A Publication of the Global Laboratory Initiative, a Working Group of the Stop TB Partnership","first-page":"134","author":"Partnership","year":"2014"},{"key":"10.1016\/j.jgar.2021.01.005_bib0115","series-title":"Susceptibility Testing of Mycobacteria, Nocardia spp., and Other Aerobic Actinomycetes","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2018"},{"key":"10.1016\/j.jgar.2021.01.005_bib0120","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1128\/AAC.01485-12","article-title":"Vancomycin AUC\/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia","volume":"57","author":"Holmes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.005_bib0125","doi-asserted-by":"crossref","first-page":"46S","DOI":"10.1046\/j.1365-2672.92.5s1.7.x","article-title":"Cellular impermeability and uptake of biocides and antibiotics in Gram-positive bacteria and mycobacteria","volume":"31","author":"Lambert","year":"2002","journal-title":"Symp Ser Soc Appl Microbiol"},{"key":"10.1016\/j.jgar.2021.01.005_bib0130","doi-asserted-by":"crossref","first-page":"925","DOI":"10.2165\/00003088-200443130-00005","article-title":"Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections","volume":"43","author":"Moise-Broder","year":"2004","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2021.01.005_bib0135","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1086\/491712","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.01.005_bib0140","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1128\/AAC.00558-10","article-title":"Structure of the Mycobacterium tuberculosis d-alanine:d-alanine ligase, a target of the antituberculosis drug d-cycloserine","volume":"55","author":"Bruning","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.005_bib0145","doi-asserted-by":"crossref","first-page":"1602308","DOI":"10.1183\/13993003.02308-2016","article-title":"World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update","volume":"49","author":"Falzon","year":"2017","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jgar.2021.01.005_bib0150","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1038\/ja.2017.56","article-title":"d-cycloserine increases the effectiveness of vancomycin against vancomycin-highly resistant Staphylococcus aureus","volume":"70","author":"Tabuchi","year":"2017","journal-title":"J Antibiot (Tokyo)"},{"key":"10.1016\/j.jgar.2021.01.005_bib0155","series-title":"ADAPT II. A Program for Simulation, Identification, and Optimal Experimental Design. User Manual","author":"D\u2019Argenio","year":"1997"},{"key":"10.1016\/j.jgar.2021.01.005_bib0160","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","article-title":"The toxicity of poisons applied jointly","volume":"26","author":"Bliss","year":"1939","journal-title":"Ann Appl Biol"},{"key":"10.1016\/j.jgar.2021.01.005_bib0165","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1086\/510247","article-title":"Isoniazid\u2019s bactericidal activity ceases because of the emergence of resistance, not depletion of Mycobacterium tuberculosis in the log phase of growth","volume":"195","author":"Gumbo","year":"2007","journal-title":"J Infect Dis"},{"key":"10.1016\/j.jgar.2021.01.005_bib0170","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1128\/AAC.00185-07","article-title":"Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations","volume":"51","author":"Gumbo","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2021.01.005_bib0175","doi-asserted-by":"crossref","first-page":"S317","DOI":"10.1093\/cid\/ciy609","article-title":"Ethionamide pharmacokinetics\/pharmacodynamics-derived dose, the role of MICs in clinical outcome, and the resistance arrow of time in multidrug-resistant tuberculosis","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.01.005_bib0180","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1128\/AAC.05546-11","article-title":"The antibiotic resistance arrow of time: efflux pump induction is a general first step in the evolution of mycobacterial drug resistance","volume":"56","author":"Schmalstieg","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2021.01.005_bib0185","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1128\/AAC.01681-08","article-title":"Pharmacokinetics\u2013pharmacodynamics of pyrazinamide in a novel in vitro model of tuberculosis for sterilizing effect: a paradigm for faster assessment of new antituberculosis drugs","volume":"53","author":"Gumbo","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 3","key":"10.1016\/j.jgar.2021.01.005_bib0190","doi-asserted-by":"crossref","first-page":"S274","DOI":"10.1093\/cid\/ciy618","article-title":"Gatifloxacin pharmacokinetics\/pharmacodynamics-based optimal dosing for pulmonary and meningeal multidrug-resistant tuberculosis","volume":"67","author":"Deshpande","year":"2018","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.01.005_bib0195","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1164\/rccm.201711-2333OC","article-title":"Drug-penetration gradients associated with acquired drug resistance in patients with tuberculosis","volume":"198","author":"Dheda","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2021.01.005_bib0200","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by Mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.jgar.2021.01.005_bib0205","series-title":"Goodman and Gilman\u2019s: The pharmacological Basis of Therapeutics","article-title":"Chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy","author":"Gumbo","year":"2018"},{"key":"10.1016\/j.jgar.2021.01.005_bib0210","series-title":"Goodman and Gilman\u2019s: The Pharmacological Basis of Therapeutics","article-title":"General principles of chemotherapy of infectious diseases","author":"Gumbo","year":"2018"},{"key":"10.1016\/j.jgar.2021.01.005_bib0215","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02253-16","article-title":"Antibiotic effects on methicillin-resistant Staphylococcus aureus cytoplasmic peptidoglycan intermediate levels and evidence for potential metabolite level regulatory loops","volume":"61","author":"Vemula","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2021.01.005_bib0220","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1093\/cid\/civ427","article-title":"Forecasting accuracy of the hollow fiber model of tuberculosis for clinical therapeutic outcomes","volume":"61","author":"Gumbo","year":"2015","journal-title":"Clin Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.jgar.2021.01.005_bib0225","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1093\/cid\/civ425","article-title":"Systematic analysis of hollow fiber model of tuberculosis experiments","volume":"61","author":"Pasipanodya","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2021.01.005_bib0230","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/ng.3548","article-title":"Genomic and functional analyses of Mycobacterium tuberculosis strains implicate ald in d-cycloserine resistance","volume":"48","author":"Desjardins","year":"2016","journal-title":"Nat Genet"},{"key":"10.1016\/j.jgar.2021.01.005_bib0235","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1128\/jb.110.3.978-987.1972","article-title":"Mechanism of d-cycloserine action: alanine racemase from Escherichia coli W","volume":"110","author":"Lambert","year":"1972","journal-title":"J Bacteriol"},{"key":"10.1016\/j.jgar.2021.01.005_bib0240","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1021\/bi00892a001","article-title":"The enzymatic synthesis of d-alanyl\u2013d-alanine. 3. On the inhibition of d-alanyl\u2013d-alanine synthetase by the antibiotic d-cycloserine","volume":"3","author":"Neuhaus","year":"1964","journal-title":"Biochemistry"},{"key":"10.1016\/j.jgar.2021.01.005_bib0245","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1021\/ml400349n","article-title":"Metabolomics reveal d-alanine:d-alanine ligase as the target of d-cycloserine in Mycobacterium tuberculosis","volume":"4","author":"Prosser","year":"2013","journal-title":"ACS Med Chem Lett"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000175?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716521000175?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T09:56:25Z","timestamp":1761990985000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716521000175"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":49,"alternative-id":["S2213716521000175"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2021.01.005","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Potency of vancomycin against Mycobacterium tuberculosis in the hollow fiber system model","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2021.01.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Ltd on behalf of International Society for Antimicrobial Chemotherapy.","name":"copyright","label":"Copyright"}]}}